What is Leerink Partnrs’ Estimate for VKTX Q1 Earnings?

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Viking Therapeutics in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the biotechnology company will earn ($0.35) per share for the quarter. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($0.97) per share. Leerink Partnrs also issued estimates for Viking Therapeutics’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.50) EPS and FY2029 earnings at $5.24 EPS.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.05). During the same quarter last year, the firm earned ($0.25) EPS.

Other equities research analysts also recently issued reports about the company. B. Riley initiated coverage on Viking Therapeutics in a research report on Friday, November 22nd. They issued a “buy” rating and a $109.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $102.00 target price on shares of Viking Therapeutics in a report on Thursday. William Blair reaffirmed an “outperform” rating on shares of Viking Therapeutics in a research note on Wednesday, November 20th. Raymond James upped their target price on Viking Therapeutics from $122.00 to $125.00 and gave the company a “strong-buy” rating in a research note on Thursday. Finally, StockNews.com raised shares of Viking Therapeutics to a “sell” rating in a research report on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $107.08.

Viking Therapeutics Stock Down 6.1 %

Shares of VKTX stock opened at $31.46 on Friday. The stock has a market cap of $3.51 billion, a P/E ratio of -33.83 and a beta of 0.90. The company’s fifty day simple moving average is $40.46 and its two-hundred day simple moving average is $54.01. Viking Therapeutics has a 52 week low of $23.81 and a 52 week high of $99.41.

Insiders Place Their Bets

In other Viking Therapeutics news, CFO Greg Zante sold 50,309 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $42.75, for a total value of $2,150,709.75. Following the completion of the transaction, the chief financial officer now owns 165,259 shares of the company’s stock, valued at approximately $7,064,822.25. This trade represents a 23.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Marianna Mancini sold 54,215 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $42.75, for a total value of $2,317,691.25. Following the completion of the transaction, the chief operating officer now directly owns 374,134 shares in the company, valued at approximately $15,994,228.50. The trade was a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 299,014 shares of company stock valued at $12,782,849. 4.70% of the stock is currently owned by insiders.

Institutional Trading of Viking Therapeutics

Large investors have recently added to or reduced their stakes in the company. International Assets Investment Management LLC increased its holdings in Viking Therapeutics by 10,775.6% in the 3rd quarter. International Assets Investment Management LLC now owns 1,004,033 shares of the biotechnology company’s stock worth $63,565,000 after buying an additional 994,801 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Viking Therapeutics in the fourth quarter worth $24,888,000. Perpetual Ltd raised its holdings in shares of Viking Therapeutics by 55.4% during the third quarter. Perpetual Ltd now owns 1,269,152 shares of the biotechnology company’s stock worth $80,350,000 after purchasing an additional 452,344 shares during the last quarter. Fiera Capital Corp acquired a new position in Viking Therapeutics during the third quarter valued at $18,443,000. Finally, Eventide Asset Management LLC boosted its holdings in Viking Therapeutics by 79.1% in the third quarter. Eventide Asset Management LLC now owns 452,969 shares of the biotechnology company’s stock valued at $28,677,000 after purchasing an additional 200,000 shares during the last quarter. Hedge funds and other institutional investors own 76.03% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.